INTRODUCTION

A large proportion of individuals with spinal cord injuries suffer from neurogenic bladder. In the United States, neurogenic bladder affects 80% of the 12 000 patients with new spinal cord injuries per year. Of these individuals, more than 80% will need some form of urinary catheterization. Individuals requiring catheterization have several options broadly falling into two categories: indwelling and intermittent catheters. Indwelling catheters are inserted via the urethra or the
abdomen (supra-pubic) and are left in situ. Urine is collected through an attached drainage bag. After insertion, indwelling catheters can remain in the bladder for an extended period of time and are regularly changed every 4-6 weeks. However, indwelling catheters have been shown to have a higher number of complications, including bladder stones, urinary tract infection (UTI), and decreased bladder capacity, in comparison to intermittent catheters. Consequently, intermittent catheterization is recommended as the gold standard for bladder management for individuals with spinal cord injury and offers several advantages over indwelling catheters. Intermittent catheters are inserted via the urethra or the abdomen, similar to indwelling catheters. In contrast to indwelling catheters, intermittent catheters can be inserted by the patient or caregiver in any location and are immediately removed after bladder drainage. Other advantages of intermittent catheters include lower risk of UTI and other complications, increased quality of life and patient autonomy, and fewer social and intimacy barriers. Additionally, intermittent catheters have higher rates of patient adherence. A study by Cameron et al found that only 71% of individuals continue to use intermittent catheters 30 years after initial use. Among the different types of intermittent catheters, uncoated and single-use hydrophilic-coated catheters are the most commonly used. Uncoated catheters are often made from medical-grade polyvinyl chloride (PVC) and require manual external gel lubrication prior to insertion. The need to manually self-lubricate may be particularly difficult for individuals with limited upper limb function. Catheterization with uncoated catheters may have a slightly increased risk of bacterial infection and other complications such as hematuria. Moreover, hydrophilic-coated catheters are coated with polyvinylpyrrolidone, a polymer that creates a lubricated surface upon exposure to water to facilitate the insertion of the catheter. Therefore, hydrophilic-coated catheters do not require manual lubrication prior to insertion. Moreover, hydrophilic-coated catheters may lead to better health outcomes due to reduced risk of infection. A previous systematic review and meta-analysis identified a 16% reduction in UTI risk associated with hydrophilic-coated catheter use in comparison to uncoated catheter use. However, the clinical benefits of hydrophilic-coated catheters come at a cost since this is the unit cost for this technology is greater than that of uncoated catheters.

Several studies have examined the cost-effectiveness of hydrophilic-coated vs uncoated catheters. Two reviews on this topic have been conducted. One review was conducted by Health Quality Ontario (HQO) in 2019. This review sought to determine the cost-effectiveness of intermittent catheterization for long-term usage and identified papers published prior to 2016. All five identified studies comparing hydrophilic-coated and uncoated catheters found hydrophilic-coated catheters to be a cost-effective option.

Another review was conducted by Saadat et al and identified six papers from 2014 to 2018; they reviewed the cost-effectiveness of single-use vs repeated-use catheters and hydrophilic-coated vs uncoated catheters. This study briefly summarized the results of each included paper but did not make any conclusions on cost the effectiveness of hydrophilic-coated catheters. Neither of these two previous studies critically evaluated the economic evaluations included in the review.

In order to fill the knowledge gaps identified in the existing literature, our systematic review sought to identify and critically evaluate the economic evaluations examining the cost-effectiveness of hydrophilic-coated vs uncoated catheters for individuals with spinal cord injury. The findings of our study can be used to provide information for public health-care payers to determine whether hydrophilic-coated catheters should be publicly funded.

2 | METHODS

2.1 | Search strategy and studies identification

We searched MEDLINE, the Excerpta Medica database (EMBASE), Cochrane Database of Systematic Reviews, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), and Emcare. There were no restrictions to the year or to the language of the publication. Our search strategy included the following key terms: "spinal cord injury," "catheterization," and "cost analysis." The full search strategy is included in Appendix A. We also conducted a bibliographic hand search of all review articles identified in the database search.

Publications were included if they: (1) included a full economic evaluation (eg, cost-effectiveness, cost-utility, or cost-benefit study) of any type of urinary catheter; (2) were conducted for individuals with spinal cord injury; and (3) were written in English or French. We excluded gray literature, conference abstracts, systematic reviews, comprehensive reviews, letters, guidelines, news articles, and policy analyses. We also excluded costing studies and cost comparison analyses.

After the removal of duplicates, titles and abstracts were independently screened by BC and MX using Covidence software. Potentially relevant full-text articles were screened by BC and MX for an inclusion or exclusion decision. Discrepancies during abstract and full-text screening were resolved by BC.

2.2 | Data collection and analysis

We evaluated the methodological quality of the included articles using the Drummond checklist. The Drummond checklist has been recommended for assessing the quality of economic evaluation studies and includes four main categories: study design, data collection, analysis, and interpretation of results. We used the Drummond checklist for quality assessment due to its broad applicability to various types of economic evaluation studies and its simple structure. The quality assessment was carried out by two reviewers (BC and MX) and discrepancies were resolved through consensus between the two reviewers.

BC and MX extracted data from the included articles. Extracted variables included study characteristics (eg, author, country study design, year of publication, population, time horizon, intervention,
and comparator) and outcomes of interest (e.g., costs and incremental cost-effectiveness ratio (ICER)). Relevant data were extracted into a Microsoft Excel database.

A meta-analysis of our data could not be conducted due to the heterogeneity in study designs, populations, time horizons, and outcomes of our included studies. Thus, only descriptive analyses were performed.

3 | RESULTS

3.1 | Study selection

Our search identified 371 citations. After the removal of 110 duplicates, we screened 261 titles/abstracts for eligibility. After title and abstract screening, 13 articles remained for full-text screening. Of these 13 articles, eight studies fulfilled the study criteria and were included for further analysis. The main reasons for exclusion at the full-text screening stage included wrong study design (n = 4) and wrong comparator used in study (n = 1). Figure 1 describes the process of study inclusion.

3.2 | Study characteristics

Table 1 presents the characteristics of the eight included studies. The eight included studies were published between 2013 and 2018 and were conducted in Canada (n = 2),4,18 the United Kingdom (n = 2),24,25 Brazil (n = 1),12 Japan (n = 1),26 Italy (n = 1),27 and the United States (n = 1).28 All studies carried out cost-utility

![FIGURE 1 PRISMA flow diagram of study inclusion and selection. n = number of studies](image-url)
| Author, year | Study type | Location | Population | Perspective | Time horizon | Intervention/ Comparator | Results |
|-------------|------------|----------|------------|-------------|--------------|--------------------------|---------|
| Bermingham et al., 2013 | Cost-utility | United Kingdom | Individuals with neurogenic bladder condition due to spinal cord injury | Services | Lifetime | Single-use hydrophilic-coated, single-use gel reservoir, sterile uncoated, and clean uncoated catheters | Clean uncoated catheters (1 per week) were cost-effective at a £20,000 threshold. Excluding clean uncoated catheters, single-use gel reservoir catheters were more cost-effective compared to hydrophilic-coated catheters (ICER: £3071 per QALY gained). |
| Clark et al., 2015 | Cost-effectiveness | United Kingdom | Individuals with spinal cord injury and chronic urinary retention | Services | Lifetime | Single-use hydrophilic-coated catheters and uncoated catheters | Hydrophilic-coated catheters were cost-effective with an ICER of £6100 per QALY gained, £3300 per life-year gained, and £79 per UTI event avoided. |
| Hakansson et al., 2016 | Cost-effectiveness | United States | Inpatients with spinal cord injury and chronic urinary retention | Services | Lifetime | Single-use hydrophilic-coated and uncoated catheters | Single-use hydrophilic-coated catheters reduced long-term health-care costs. Hydrophilic-coated catheters were more cost-effective than uncoated catheters, saving $10,184, gaining 0.55 QALY, and avoiding 16 UTIs per person on average. |
| Rognoni and Tarricone, 2017 | Cost-effectiveness | Italy | Individuals with spinal cord injury who use intermittent catheterization in a community setting | Health-care service | Lifetime | Single-use hydrophilic-coated and single-use uncoated catheters | Hydrophilic-coated catheters were cost-effective compared to uncoated catheters (ICER: €24,405 per QALY gained and €20,761 euros per life-year gained). |
| Watanabe et al., 2017 | Cost-effectiveness | Japan | Inpatients with spinal cord injury and chronic urinary retention | Payers | Lifetime | Single-use hydrophilic-coated and uncoated catheters | Hydrophilic-coated catheters were cost-effective compared to uncoated catheters with an ICER of ¥3,826,351 per QALY gained and ¥1,639,562 per life-year gained. |
| Welk et al., 2018 | Cost-effectiveness | Canada | Individuals with neurogenic bladder dysfunction due to spinal cord injury | Health-care service | Lifetime | Single-use hydrophilic-coated and uncoated catheters | Hydrophilic-coated catheters were cost-effective compared to uncoated catheters (ICER: $66,462 per QALY gained). |
| Health Quality Ontario, 2019 | Cost-utility | Canada | Inpatients and outpatients with chronic urinary retention due to spinal cord injury | Health-care service | 5-year | Single-use hydrophilic-coated, repeated-use uncoated (1/day and 1/week), and single-use uncoated catheters | ICER for single-use hydrophilic-coated vs repeated-use uncoated catheters: $5.5 million per QALY gained. ICER for single-use hydrophilic-coated vs single-use uncoated catheters: $3 million per QALY gained. |

**TABLE 1** Characteristics of economic evaluation studies examining hydrophilic-coated vs uncoated catheters for individuals with spinal cord injury included for analysis.
3.3 | Quality assessment

Table 2 outlines the methodological quality assessment of the included economic evaluation studies based on the Drummond checklist. Overall, the eight included studies were well reported and no main methodological issues were identified. However, most of the included studies did not clearly state or justify the perspective of the analysis or justify the type of economic evaluation used in the study.

3.4 | Summary of the study methods and results

The results of the included studies are summarized in Table 1. Several economic evaluations have been conducted regarding the use of different types of catheters for individuals with spinal cord injury. The first economic evaluation of single-use and repeated-use intermittent catheters was conducted by Bermingham et al for the National Institute for Health and Clinical Excellence (NICE) in the United Kingdom. This cost-utility analysis used a Markov model to examine costs, quality-adjusted life years (QALYs), and incremental cost per QALY gained over a lifetime horizon from a UK National Health Services perspective. The Markov model examined the short-term sequelae of UTI and assumed the same risk of UTI between different catheter types. The input for the Markov model was based largely on the authors’ systematic review and meta-analysis of randomized control trial and random crossover trial papers published between 2002 and 2011. Bermingham et al found that hydrophilic-coated catheters were not cost-effective when compared to uncoated catheters reused for the entire week (one per week) or daily (one per day). However, excluding uncoated catheter reuse, hydrophilic-coated catheters was observed to be less costly and have better QALYs. Sensitivity analyses conducted by the authors demonstrated that clean uncoated catheters would not be the most cost-effective bladder management option if the patient used more than one clean uncoated catheter per day.

The Bermingham et al paper was quickly followed by a cost-effectiveness study conducted by Clark et al, also based in the United Kingdom. The study was conducted over a lifetime horizon from a UK National Health Services perspective. Clark et al used the model by Bermingham and colleagues as a foundation, but examined long-term sequelae of UTI and applied a UTI risk reduction rate of 21% for individuals who used hydrophilic-coated catheters in comparison to those who used uncoated catheters. Additionally, Clark et al used randomized control trials of solely adult spinal cord injury participants as their parameter input. The authors examined costs, QALYs, cost per life-year gained, and cost per UTI event. At a cost-effectiveness threshold of £20 000-30 000 per QALY gained, the authors found hydrophilic-coated catheters to be cost-effective. Subsequent economic evaluation studies on this topic used Markov models based on the model developed by Bermingham et al, the model developed by Clark et al, or both.

Another cost-effectiveness analysis was conducted by Hakansson et al. The authors used a Markov model, based on the model developed by Bermingham et al, that included various health states for potential complications including epididymitis, strictures, and bladder stones. The study did not distinguish between costs of the different catheter types, except that uncoated catheters had an additional cost of £0.13 per catheter for the cost of lubricant. Hakansson et al found that single-use hydrophilic-coated catheters reduced long-term health-care costs and were more cost-effective than uncoated catheters. Their sensitivity analyses revealed that single-use hydrophilic-coated catheters should remain cost-effective until the cost of a single hydrophilic-coated catheter becomes equal to or greater than £2.84.

In 2017, Rognoni and Tarricone also conducted a cost-effectiveness analysis comparing single-use hydrophilic-coated and single-use uncoated catheters. They use a Markov model, based on the one developed by Bermingham et al, to investigate the costs, life-years gained, and QALYs gained for the two types of catheters from the Italian health-care service perspective over a lifetime horizon. This study examined the short-term consequences of UTIs and hematuria. They also included model parameters for other infections and inflammations relevant to catheterization including epididymitis/orchitis, urethritis, prostatitis, strictures, false passage, and bladder stones. The source of data for model input consisted of health-care resource utilization derived from an e-survey completed by a group of 25 urologists and neuro-urologists. At Italian cost-effectiveness threshold values of €25 000-40 000, €36 500, €60 000, and €66 400 per QALY gained and at the United Kingdom-specific threshold value recommended by NICE of £20 000-30 000 per QALY gained, Rognoni and Tarricone found single-use hydrophilic-coated catheters to be cost-effective compared to uncoated catheters.

A fourth economic evaluation study was conducted by Watanabe et al and sought to investigate the cost-effectiveness of single-use hydrophilic-coated catheters vs uncoated catheters. The Markov model was based on the model developed by Clark et al, but with Japanese data derived from clinician surveys, published literature, and national statistics. The model examined cost per QALY gained, cost per life-year gained, and cost per UTI event avoided over a lifetime horizon from a Japanese payer perspective. Applying a cost-effectiveness threshold of ¥6 700 000 per QALY gained (US$55 372/
TABLE 2 Results of the economic evaluation quality assessment by Drummond et al.21

| Study design                                                                 | Welk (2018) | Watanabe (2017) | Truzzi (2018) | Rognoni (2017) | Clark (2016) | Birmingham (2013) | Hakkanson (2016) | HQO (2019) |
|-----------------------------------------------------------------------------|--------------|-----------------|---------------|----------------|--------------|-------------------|-------------------|------------|
| 1. The research question is stated                                         | Yes          | Yes             | Yes           | Yes            | Yes          | Yes               | Yes               | Yes        |
| 2. The economic importance of research question is stated                   | Yes          | Yes             | No            | Yes            | Yes          | Yes               | Yes               | Yes        |
| 3. The viewpoint(s) of the analysis is clearly stated and justified         | Not clear    | No              | No            | No             | No           | No                | No                | No         |
| 4. The rationale for choosing the alternative programmes or interventions compared is stated | Yes          | No              | Yes           | Yes            | Yes          | Yes               | Yes               | Yes        |
| 5. The alternatives being compared are clearly described                    | Yes          | No              | Yes           | Yes            | Yes          | Yes               | Yes               | Yes        |
| 6. The form of economic evaluation used is stated                          | Yes          | Yes             | Yes           | Yes            | Yes          | Yes               | No                | Yes        |
| 7. The choice of form of economic evaluation is justified in relation to the questions addressed | No           | No              | No            | No             | No           | No                | No                | Yes        |

Data collection

| 8. The source(s) of effectiveness estimates used are stated                | Yes          | Yes             | Yes           | Yes            | Yes          | Yes               | Yes               | Yes        |
| 9. Details of the design and results of effectiveness study are given (if based on a single study) | Not appropriate | Not appropriate | Not appropriate | Not appropriate | Not appropriate | Not appropriate | Not appropriate | Not appropriate |
| 10. Details of the method of synthesis or meta-analysis of estimates are given (if based on an overview of a number of effectiveness studies) | Yes          | Yes             | Yes           | Yes            | Yes          | Yes               | Yes               | Yes        |
| 11. The primary outcome measure(s) for the economic evaluation is clearly stated | Yes          | No              | Yes           | Yes            | Yes          | Yes               | Yes               | Yes        |
| 12. Methods to value health states and other benefits are stated           | Yes          | Yes             | Yes           | Yes            | Yes          | Yes               | Yes               | Yes        |
| 13. Details of the subjects from whom valuations were obtained are given   | Yes          | No              | No            | No             | No           | No                | No                | Yes        |
| 14. Productivity changes (if included) are reported separately             | Yes          | Not appropriate | Not appropriate | Not appropriate | Not appropriate | Not appropriate | Not appropriate | Not appropriate |
| 15. The relevance of productivity changes to the study question is discussed | Yes          | Not appropriate | Not appropriate | Not appropriate | Not appropriate | Not appropriate | Not appropriate | Not appropriate |
| 16. Quantities of resources are reported separately from their unit costs  | Yes          | Yes             | Yes           | Yes            | Yes          | Yes               | Yes               | Yes        |
| 17. Methods for the estimation of quantities and unit costs are described   | Yes          | Yes             | Yes           | Yes            | Yes          | Yes               | Yes               | Yes        |
| 18. Currency and price data are recorded                                  | Yes          | Yes             | Yes           | Yes            | No           | Yes               | Yes               | Yes        |
| 19. Details of currency of price adjustments for inflation or currency conversion are given | Yes          | No              | Not clear     | No             | No           | No                | No                | Yes        |
| 20. Details of any model used are given                                   | Yes          | Yes             | Yes           | Yes            | Yes          | Yes               | Yes               | Yes        |

(Continues)
TABLE 2 (Continued)

| II | Welk (2018) | Watanabe (2017) | Truzzi (2018) | Rognoni (2017) | Clark (2016) | Birmingham (2013) | Hakkanson (2016) | HQO (2019) |
|---|-------------|-----------------|--------------|---------------|-------------|-------------------|------------------|------------|
| 21. The choice of model used and the key parameters on which it is based are justified | Yes | No | No | No | Yes | Yes | Yes | Yes |
| Analysis and interpretation of results | | | | | | | | |
| 22. Time horizon of costs and benefits is stated | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 23. The discount rate(s) is stated | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 24. The choice or rate(s) is justified | Yes | No | No | Yes | Yes | No | Yes | Yes |
| 25. An explanation is given if costs or benefits are not discounted | Not appropriate | Not appropriate | Not appropriate | Not appropriate | Not appropriate | Not appropriate | Not appropriate | Not appropriate |
| 26. Details of statistical tests and confidence intervals are given for stochastic data | No | No | No | No | Yes | No | No | Yes |
| 27. The approach to sensitivity analysis is given | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 28. The choice of variables for sensitivity analysis is justified | No | Yes | No | Yes | Yes | Yes | Yes | Yes |
| 29. The ranges over which the variables are varied are stated | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 30. Relevant alternatives are compared | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 31. Incremental analysis is reported | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 32. Major outcomes are presented in a disaggregated as well as an aggregated form | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 33. The answer to the study question is given | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 34. Conclusions follow from the data are reported | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 35. Conclusions are accompanied by the appropriate caveats | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Stated source(s) of funding | Yes | Yes | Yes | Yes | Yes | Yes | No | No |
| Stated conflict(s) of interest | Yes | Yes | Yes | Yes | Yes | Yes | No | No |
QALY), Watanabe et al found hydrophilic-coated catheters to be cost-effective compared to uncoated catheters.

In 2018, Truzzi et al conducted a cost-effectiveness analysis from a Brazilian public payer perspective over a lifetime horizon to examine the cost per QALY gained of single-use hydrophilic-coated catheters vs uncoated catheters. Their Markov model was based on the model used by Clark et al, but included separate health states for first- and second-line antibiotic-resistant UTIs. The authors conducted two scenario analyses, one including all possible adverse events (ie, UTIs, bladder stones, kidney stones, urethral injury, and urosepsis) and one including only UTIs. Accounting for all possible adverse events and applying a cost-effectiveness threshold of $147 000 per QALY gained, the authors found single-use hydrophilic-coated catheters to be cost-effective in comparison to uncoated catheters. When accounting for only UTIs, hydrophilic-coated catheters reduced UTI risk by 6% for an additional cost of $31 240.

A cost-effective analysis was conducted by Welk et al in 2018. The study used a Markov model, derived from the one used by Clark et al, to examine the incremental costs, QALYs, life-year gained, and number of UTIs avoided over a lifetime horizon from a Canadian public payer perspective (ie, perspective of the Ontario Ministry of Health and Long-term Care). This Markov model was based on the model developed by Clark et al to investigate the long-term sequelae of UTI and used data from previous meta-analyses and provincial and national data from the government of Ontario and Statistics Canada. Welk et al used cost-effectiveness thresholds of $20 000-100 000 per QALY gained and $50 000-100 000 per QALY gained and found hydrophilic-coated catheters to be cost-effective compared to uncoated catheters.

Finally, an economic evaluation studying various catheter types was conducted by HQO in 2019. The study included data for inpatients and outpatients with chronic urinary retention due to spinal cord injury and examined the incremental cost per QALY of hydrophilic-coated vs uncoated catheters over a 5-year time horizon from the perspective of the Ontario Ministry of Health and Long-term Care. The HQO report adapted the Markov model used by Bermingham et al, assuming equal risk of complications between the different catheter types and examining short-term consequences of complications such as UTIs and hematuria. At a cost-effectiveness threshold of $100 000 per QALY gained, the HQO report found single-use uncoated catheters to be 100% cost-effective, but not hydrophilic-coated catheters.

Using ICER per QALY gained as the primary measure of cost-effectiveness, the evidence surrounding the cost-effectiveness of hydrophilic-coated catheters in comparison to other types of catheters varied. Five studies observed hydrophilic-coated catheters to be cost-effective compared to uncoated catheters. Two studies found hydrophilic-coated catheters to be not cost-effective compared to uncoated catheters and one study estimated that hydrophilic-coated catheters reduced the long-term health-care costs compared to uncoated catheters.

Several study-related factors help to explain the discrepancy in results observed. First, the results appear to depend on the primary treatment comparator in the economic evaluations. In the study by Bermingham et al, uncoated catheters reused for a full week was selected as the comparator to all other treatment options. None of the other treatment comparators evaluated were considered cost-effective when compared to repeated-use uncoated catheters. This is not surprising given the considerable cost difference between a single uncoated catheter, vs the 25-35 single-use hydrophilic-coated catheters that patients would require in a week. However, when repeated-use uncoated catheters were excluded from the analysis, hydrophilic-coated catheters were considered less costly with better outcomes compared to single-use uncoated catheters and gel reservoir was considered cost-effective compared to hydrophilic-coated catheters. Similarly, in the HQO report, the reference case analysis compared hydrophilic-coated catheters to uncoated catheters reused for a full week. The ICER decreased from $3.7 million per QALY to $3.1 million per QALY when repeated-use uncoated catheters were excluded. All other studies identified in our review used single-use uncoated catheters as the treatment comparator. As noted in several of the studies included in our review, including the study by Bermingham et al, the reuse of uncoated catheters is not supported by health-care governing organizations and is considered off-label use. Many countries have adapted single-use uncoated catheters as the minimum standard for clean intermittent catheterization. Thus, a comparison of approved intermittent catheters would result in all studies observing hydrophilic-coated catheters to be cost-effective compared to uncoated catheters with the exception of the HQO report.

Second, the discrepancy in the cost-effectiveness outcomes of our included studies may be related to whether long-term health impacts were considered. The model design for the economic evaluations identified in our systematic review can be separated into two categories: studies that evaluated short-term health effects and studies that considered the long-term health implications of using different catheter types. Studies focused on the long-term implications considered the impact of secondary complications on renal function, which increased the benefits associated with reducing UTIs and other renal complications. As a result, studies including the long-term impact on renal function typically had greater incremental QALYs (between 0.26 and 0.72) in comparison to studies examining short-term impact (0.077-0.18). This difference could partially explain the discrepancy in cost-effectiveness outcomes, with larger incremental QALYs resulting in lower

### 4 | DISCUSSION

Our study sought to assess the cost-effectiveness of hydrophilic-coated catheters compared to other types of urinary catheters among the spinal cord injury population. We identified eight studies that reported the cost-effectiveness of hydrophilic-coated catheters in the spinal cord injury population, evaluating seven different types of catheters.

Several study-related factors help to explain the discrepancy in results observed. First, the results appear to depend on the primary treatment comparator in the economic evaluations. In the study by Bermingham et al, uncoated catheters reused for a full week was selected as the comparator to all other treatment options. None of the other treatment comparators evaluated were considered cost-effective when compared to repeated-use uncoated catheters. This is not surprising given the considerable cost difference between a single uncoated catheter, vs the 25-35 single-use hydrophilic-coated catheters that patients would require in a week. However, when repeated-use uncoated catheters were excluded from the analysis, hydrophilic-coated catheters were considered less costly with better outcomes compared to single-use uncoated catheters and gel reservoir was considered cost-effective compared to hydrophilic-coated catheters. Similarly, in the HQO report, the reference case analysis compared hydrophilic-coated catheters to uncoated catheters reused for a full week. The ICER decreased from $3.7 million per QALY to $3.1 million per QALY when repeated-use uncoated catheters were excluded. All other studies identified in our review used single-use uncoated catheters as the treatment comparator. As noted in several of the studies included in our review, including the study by Bermingham et al, the reuse of uncoated catheters is not supported by health-care governing organizations and is considered off-label use. Many countries have adapted single-use uncoated catheters as the minimum standard for clean intermittent catheterization. Thus, a comparison of approved intermittent catheters would result in all studies observing hydrophilic-coated catheters to be cost-effective compared to uncoated catheters with the exception of the HQO report.

Second, the discrepancy in the cost-effectiveness outcomes of our included studies may be related to whether long-term health impacts were considered. The model design for the economic evaluations identified in our systematic review can be separated into two categories: studies that evaluated short-term health effects and studies that considered the long-term health implications of using different catheter types. Studies focused on the long-term implications considered the impact of secondary complications on renal function, which increased the benefits associated with reducing UTIs and other renal complications. As a result, studies including the long-term impact on renal function typically had greater incremental QALYs (between 0.26 and 0.72) in comparison to studies examining short-term impact (0.077-0.18). This difference could partially explain the discrepancy in cost-effectiveness outcomes, with larger incremental QALYs resulting in lower
incremental cost per QALY. The only exception was the study by Rogoni et al an economic evaluation of short-term outcomes that observed an incremental QALY of 0.84.27 This exception can be explained by the measure of reduction in symptomatic UTI between hydrophilic-coated catheters and uncoated catheters used in the model inputs. For the Bermingham et al paper and the HQO report, the measure of benefit was the difference in number of individuals experiencing at least one UTI.4,24 Moreover, Rogoni et al incorporated the difference in the average number of UTIs experienced per person per month. The average number of UTIs was selected by us for users of uncoated catheters.18 These additional benefits, including savings in societal costs, would be lost if decision makers only look at the contrasting results.

Finally, the unit cost of treatment may have notably impacted the incremental cost of hydrophilic-coated catheters resulting in a discrepancy in the economic evaluation outcomes. Both Bermingham et al and Hakansson et al assumed similar unit costs for hydrophilic-coated and uncoated catheters.24,28 With the additional cost of lubricant for the administration of uncoated catheters, the total cost for treatment with uncoated was greater than hydrophilic-coated catheters. As such, both studies observed a decrease in cost with hydrophilic-coated catheters in comparison to uncoated catheters. The daily cost premium for hydrophilic-coated catheters estimated in other economic evaluations ranged between $2.49 US dollars ($1.75 per day), reported by Clark et al,25 and $8.96 ($10.80 Canadian per day), reported by Welk et al18. The largest daily cost differential for catheters was reported by the HQO report at $24.24 per day ($29.20 Canadian per day).1 This cost differential resulted in a higher total lifetime incremental cost of $183,243 for hydrophilic-coated catheter treatment compared to uncoated catheters.4 This is about 3.8 times higher than the cost differential reported by Welk et al examined in the same jurisdiction at the same time.18 In a single-payer health-care system such as Canada, it seems likely that the per unit costs could be significantly reduced with large-scale purchase agreements.

Furthermore, we found that there appeared to be evidence for additional economic benefits when a societal perspective was considered. For example, Welk et al found that hydrophilic-coated catheters dominated uncoated catheters in terms of short- and long-term sick leaves, early retirement, and early death, implying that societal costs for users of hydrophilic-coated catheters are less than those for users of uncoated catheters.18 These additional benefits, including savings in societal costs, would be lost if decision makers only look at the contrasting results.

In terms of future directions, further studies are needed to evaluate the short-term and long-term effects of hydrophilic-coated catheter use on UTI. A systematic review and meta-analysis of intermittent catheterization with hydrophilic-coated and non-hydrophilic-coated catheters noted that many studies were randomized control trials with small samples and had attrition bias as a result of greater dropouts in the hydrophilic-coated catheter arm.27 Another systematic review and meta-analysis on the same topic, noted similar limitations as well as insufficient study sample sizes and no studies with observation periods beyond 1 year.4 Thus, there is a need for better evidence on this important clinical outcome. In addition to studies on hydrophilic-coated catheter use and UTI risk, there is also a need for additional evidence on the impact of hydrophilic-coated catheter use on long-term renal function. The first economic evaluation model incorporating long-term progression in renal function was developed with the guidance of urologists and spinal cord injury rehabilitation specialists.25 Since this study, the same model has been adapted in three other countries by other research teams12,18,26 suggesting that this model may be a better reflection of clinical reality. However, the recent HQO report excluded long-term renal function outcomes following consultation with expert opinion and a NICE report on childhood UTI.4 Studies on the chronic use of hydrophilic-coated catheters on renal function would be beneficial in providing evidence on the long-term impacts of the use of different catheter types and provide stronger justification on whether to limit an economic evaluation to short-term outcomes. There is also a need for greater transparency on the acquisition cost of hydrophilic-coated catheters. As described earlier, the large range in unit costs used in different economic evaluations may be causing a large discrepancy in incremental cost and resulting in vastly different incremental cost per QALYs. Given that individuals are estimated to use between three to five catheters per day, even small differences in unit cost of the device will have large incremental costs over a lifetime. Finally, the inclusion of repeated-use uncoated catheters as a comparator requires a larger discussion and guidance by government health-care agencies on the appropriateness of off-label interventions in economic evaluations. This will likely require a broader discussion on the reasons why individuals are administering medical interventions beyond its intended use and may broach the subject of health-care accessibilities, barriers, and funding.

A strength of our study was the use of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and the Drummond checklist for economic evaluations to identify, assess, and critically examine our included studies. Nevertheless, our study does have several limitations that should be considered. First, we did not search gray literature databases, which may have led to the exclusion of a few potentially relevant citations. Thus, it is possible that our search missed economic analyses conducted by government agencies or health-care organizations. Second, whether hydrophilic-coated catheters were considered cost-effective for each study was dependent on the study author’s interpretation of the results. For the most part, this interpretation was based on the common cost-effectiveness thresholds reported in the country where the study was conducted. Third, most of our included studies have limited generalizability. The generalizability of the economic evaluation studies we included tended to be limited to the specific population specified in their respective study designs.

Our critical evaluation of the literature suggests that the evidence is pointing toward hydrophilic-coated catheters being cost-effective. The comparator intervention, inclusion of long-term outcomes, and the unit cost of the catheter appear to influence the estimated cost-effectiveness hydrophilic-coated catheters.
Our findings are relevant, particularly among the spinal cord injury population, who are often injured when they are young, and are expected to use intermittent catheters for decades. Financial support of hydrophilic-coated catheters may improve the quality of life and reduce urinary infections, and thus reduce the significant number of patients that switch to indwelling catheters, a medically inferior bladder management method.

CONFLICT OF INTEREST
Ms Xi reports an unrestricted grant by Spinal Cord Injury Ontario and is a part of the Spinal Cord Injury Ontario Pee For Free working group steering committee. Ms Pakosh reports an unrestricted grant by Spinal Cord Injury Ontario. Dr Elterman has nothing to disclose. Dr Welk has nothing to disclose. Dr Chan reports an unrestricted grant by Spinal Cord Injury Ontario and is a part of the Spinal Cord Injury Ontario Pee For Free working group steering committee.

FUNDING INFORMATION
This study was supported by Spinal Cord Injury Ontario through an unrestricted grant. The authors had independent control over study methods, analysis, and interpretation of the results. Spinal Cord Injury Ontario was provided with an earlier draft of the manuscript for review. Spinal Cord Injury Ontario did not have editorial control over the manuscript content.

ORCID
Min Xi https://orcid.org/0000-0002-8398-7239
Dean S. Elterman https://orcid.org/0000-0003-1507-7783
Blayne Welk https://orcid.org/0000-0001-7093-558X
Brian C. F. Chan https://orcid.org/0000-0001-5037-0446

REFERENCES
1. The National SCI Statistical Center. Spinal cord injury facts and figures at a glance. J Spinal Cord Med. 2012;35(1):68–9. https://doi.org/10.1179/204577212X132377834824262
2. Manack A, Motsko SP, Haag-Molkenteller C, Dmochowski RR, Goehring EL, Nguyen-Khoa BA, et al. Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database. Neurourol Urodyn. 2011;30(3):395–401.
3. Lai EC, Yang YHK, Kuo HC. Complication rate of neurogenic lower urinary tract dysfunction after spinal cord injury in Taiwan. Int Urol Nephrol. 2014;46(6):1063–71.
4. Health Quality Ontario. Intermittent catheters for chronic urinary retention: A health technology assessment. Ont Health Technol Assess Ser. 2019;19(1):1–53. Available from http://www.hqontario.ca/evidence-to-improve-care/journal-ontario-health-technology-assessment-series
5. Consortium for Spinal Cord Medicine. Bladder management for adults with spinal cord injury: a clinical practice guideline for health-care providers. J Spinal Cord Med. 2006;29(5):527–73.
6. Linsenmeyer TA. Catheter-associated urinary tract infections in persons with neurogenic bladders. J Spinal Cord Med. 2018;41(2):132–41.
7. Mitsui T, Minami K, Furuno T, Morita H, Koyanagi T. Is suprapubic cystostomy an optimal urinary management in high quadriplegics? Europ Urol. 2000;38(4):434–8. https://doi.org/10.1159/000020320
8. Feifer A, Corcos J. Contemporary role of suprapubic cystostomy in treatment of neuropathic bladder dysfunction in spinal cord injured patients. Neurourol Urodyn. 2008;27(6):475–9.
9. De Ridder DJ, Everaert K, Fernández LG, Valero JF, Durán AB, Abrisqueta MJ, et al. Intermittent catheterisation with hydrophilic-coated catheters (SpeediCath) reduces the risk of clinical urinary tract infection in spinal cord injured patients: a prospective randomised parallel comparative trial. Euro Urol. 2005;48(6):991–5.
10. Hill TC, Baeverstock R, Carlson KV, Estey EP, Gray GJ, Hill DC, et al. Best practices for the treatment and prevention of urinary tract infection in the spinal cord injured population: the Alberta context. Can Urol Assoc J. 2013;7(3–4):122–30.
11. Cameron AP, Wallner LP, Tate DG, Sarma AV, Rodriguez GM, Clemens JQ, et al. Bladder management after spinal cord injury in the United States 1972 to 2005. J Urol. 2010;184(1):213–7.
12. Truzzi JC, Teich V, Pepe C. Can hydrophilic coated catheters be beneficial for the public healthcare system in Brazil?—A cost-effectiveness analysis in patients with spinal cord injuries. Int Braz J Urol. 2018;44(1):121–31.
13. Zlatev DV, Shem K, Elliott CS. How many spinal cord injury patients can catheterize their own bladder? The epidemiology of upper extremity function as it affects bladder management. Spinal Cord. 2016;54(4):287–91.
14. Spinu A, Onose G, Daia C, Panțu C, Anghelescu A, Onose L, Mihăescu A. Intermittent catheterization in the management of post spinal cord injury (SCI) neurogenic bladder using new hydrophilic, with lubrication in close circuit devices—our own preliminary results. J Med Life. 2012;5(1):21–8.
15. Christison K, Walter M, Wyndaeele JJ, Kennelly M, Kessler TM, Noonan VK, et al. Intermittent catheterization: the devil is in the details. J Neurotrauma. 2018;35(7):985–9.
16. Jeong SJ, Oh SJ. Recent updates in urinary catheter products for the neurogenic bladder patients with spinal cord injury. Korean J Neurotrauma. 2019;15:77–87.
17. Rognoni C, Tarricone R. Intermittent catheterisation with hydrophilic and non-hydrophilic urinary catheters: systematic literature review and meta-analyses. BMC Urol. 2017;17(1):4.
18. Welk B, Isaranuwatchai W, Krassioukov A, Torp LH, Elterman D. Cost-effectiveness of hydrophilic-coated intermittent catheters compared with uncoated catheters in Canada: a public payer perspective. J Med Econ. 2018;21(7):639–48.
19. Saadat SH, Shepherd S, Van Asseldonk B, Elterman DS. Clean intermittent catheterization: Single use vs. reuse. Can Urol Assoc J. 2018;13(2):64–9.
20. Covidence [Computer program]. Veritas Health Innovation. Melbourne, Australia. [cited 2020 Oct 5]. Available from www.covidence.org
21. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ. 1996;313(7052):275–83.
22. Gonzalez-Perez JG. Developing a scoring system to quality assess economic evaluations. Eur J Health Econ. 2002;3(2):131–6.
23. Doran CM. Critique of an economic evaluation using the Drummond checklist. Appl Health Econ Health Policy. 2010;8(6):357–9.
24. Berrimingham SL, Hodgkinson S, Wright S, Hayter E, Spinks J, Pellowe C. Intermittent self catheterisation with hydrophilic gel reservoir, and non-coated catheters: A systematic review and cost effectiveness analysis. BMJ. 2013;346:e8639.
25. Clark JF, Mealing SJ, Scott DA, Vogel LC, Krassioukov A, Spinelli M, et al. A cost-effectiveness analysis of long-term intermittent catheterisation with hydrophilic and uncoated catheters. Spinal Cord. 2015;54(1):73–7.
26. Watanabe T, Yamamoto S, Gotoh M, Saitoh T, Yokoyama O, Murata T, et al. Cost-effectiveness analysis of long-term intermittent self-catheterization with hydrophilic-coated and uncoated catheters in patients with spinal cord injury in Japan. Low Urin Tract Symptoms. 2017;9(3):142–50.

27. Rognoni C, Tarricone R. Healthcare resource consumption for intermittent urinary catheterisation: Cost-effectiveness of hydrophilic catheters and budget impact analyses. BMJ open. 2017;7(1):e012360.

28. Häkansson MÅ, Neovius K, Lundqvist T. Healthcare costs associated with hydrophilic-coated and non-coated urinary catheters for intermittent use in the United States. Urol Nurs. 2016;36(5):233–42.

29. Patel DP, Herrick JS, Stoffel JT, Elliott SP, Lenherr SM, Presson AP, et al. Reasons for cessation of clean intermittent catheterization after spinal cord injury: Results from the Neurogenic Bladder Research Group spinal cord injury registry. Neurourol Urodyn. 2020;39(1):211–9.

How to cite this article: Xi M, Elterman DS, Welk B, Pakosh M, Chan BCF. Cost-effectiveness of hydrophilic-coated urinary catheters for individuals with spinal cord injury: A systematic review. BJUI Compass. 2021;2:71–81. https://doi.org/10.1111/bco2.63

APPENDIX A

SEARCH STRATEGY

Search Strategy: Ovid MEDLINE(R) ALL <1946 to October 18, 2019>

1. [Question: What are the economics of intermittent catheter use for individuals with Spinal Cord Injury?]
2. [Population: Spinal Cord Injury/Neurogenic Bladder]
3. exp Spinal Cord Injuries/
4. exp Spinal Injuries/
5. exp Spine/ and trauma*.tw,kw.
6. exp Paraplegia/
7. exp Quadriplegia/
8. Urinary Bladder, Neurogenic/
9. (spine or spinal or vertebra*) adj3 (injur* or contusion* or trauma* or transection* or laceration* or compression*).tw,kw.
10. (paraplegi* or quadriplegi* or quadripares* or tetraplegi*).tw,kw.
11. (myelopath* adj2 (traumatic or post-traumatic or post traumatic or compressive)).tw,kw.
12. (bladder* adj3 (neurogen* or neuropath*)).tw,kw.
13. or/3-12
14. [Intervention: Catheters/Catheterization]
15. exp Catheters/
16. exp Catheterization/
17. (catheter* or self-catheter*).tw,kw.
18. or/15-17
19. [Outcomes: Economic/Cost Analysis]
20. economics/
21. "costs and cost analysis"/
22. cost-benefit analysis/
23. "cost savings"/
24. "cost of illness"/
25. exp health care costs/
26. exp health expenditures/
27. exp economics, hospital/
28. exp economics, medical/
29. health care sector/
30. quality-adjusted life years/
31. (cost* adj3 (analys* or compar* or measur* or effect* or benefi* or utilit* or saving* or variation* or minimization* or minimisation* or assess* or "out-of-pocket" or increment* or health care or healthcare or variance* or overall or averag* or direct or indirect or illness* or total* or data* or ratio* or outpatient* or inpatient* or patient* or clinic* or device* or "per life" or lifetime* or estimat* or differ* or burden*).tw,kw.
32. ((econom* or financ* or budget*) adj3 (evaluat* or impact* or analys* or burden or consequence* or strateg* or model* or comparator*).tw,kw.
33. (life year* adj3 (quality-adjusted or quality adjusted)).tw,kw.
34. or/20-33
35. 13 and 18 and 34

***************************